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ABSTRACT 
Drug-facilitated sexual assaults are a public health and safety concern.  Liquid 
chromatography paired with tandem mass spectrometry is theoretically capable of 
detecting the scope of drugs commonly encountered in these types of cases.  An 
analytical method was developed for the quantitative analysis of 40 drugs designated by 
Academy Standards Board 121 “Standard for the Analytical Scope and Sensitivity for 
Forensic Toxicological Testing of Urine in Drug Facilitated Crime” (ASB 121).  The 
targeted analytes spanned a range of drug classes including antidepressants, 
antihistamines, barbiturates, benzodiazepines, cannabinoids, stimulants, and opioids. 
The final method utilized supported liquid extraction, followed by liquid 
chromatography tandem mass spectrometry with electrospray ionization in simultaneous 
positive and negative mode.  Multiple reaction monitoring allowed quantification of 
analytes along with stable isotope internal standards.  Validation parameters assessed 
included linearity, bias, precision, limit of detection, lower limit of quantitation, 





was able to extract 36 of the 40 target analytes and the developed analytical method was 
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1.1 Drug Facilitated Sexual Assault 
Drug-facilitated crimes are a public health and safety concern.  A sexual assault is 
considered drug-facilitated if the victim is subjected to nonconsensual acts while 
incapacitated due to the effects of drugs, and is therefore unable to consent (1).  The drug 
ingestion may be voluntary or involuntary, so long as the effects of the drugs deprive a 
person of the mental capacity to consent to sexual acts. Drug-facilitated sexual assault 
(DFSA) cases may present with clinical patterns of sudden intoxication, intoxication out 
of proportion with consumption, waking in an unexpected location, clothing removed or 
on inside out, clothing stained with biological fluids, genital soreness, and loss of 
memory (2).  Drugs commonly encountered in DFSA have clinical effects that include 
strong sedation, lack of inhibition, muscle relaxation, and memory loss.  Drugs 
purposefully used for DFSA may have no odor, color, or taste, have a rapid onset of 
action and are generally easily obtained (1).   
The true incidence of DFSA is difficult to determine for several reasons.  Victims 
may have limited memory of the events which can prevent or delay reporting.  This in 
turn can lead to a delay in collection of biological samples and impact toxicological 
detection.   While DFSA can occur through involuntary ingestion of a drugs (“drink 
spiking”), the majority of DFSA cases occur after the voluntary ingestion of drugs or 
alcohol (2).  In one study of drug screens of 76 cases of DFSA: voluntary alcohol use was 





26% reported recreational drug use (3).  Drugs unknowingly consumed were detected in 
20% of the 76 subjects (3).  DFSA may include a combination of drugs consumed 
voluntarily and involuntarily.  The detection of more than one drug in DFSA cases is 
common, with ethanol being the most commonly identified substance in samples with 
multiple analytes (4,5,6,7). In an analysis of 1000 cases of suspected DFSA, a single drug 
was detected in just over a quarter of the cases, while more than half of the cases had two 
or more drugs detected (6).   
Toxicological detection of drugs used in DFSA cases can be very challenging.  
Analyte concentration may be very low because of the short elimination half-lives typical 
to some of the drugs used combined with delays between the offense, reporting and 
sampling.  In addition, the types of analytes encountered can wildly vary.  A single 
method capable of detecting the majority of the scope of drugs utilized in DFSA must be 
amenable to drugs of varying acidity, polarity, and size while maintaining the sensitivity 
necessary to detect the low levels of drugs typical for DFSA cases.  Liquid-
chromatography mass spectrometry (LC-MS) is one methodology capable of meeting the 
needs of DFSA case samples.    
1.2 LC-MS Instrumentation 
Liquid chromatography-mass spectrometry (LC-MS) consists of a liquid 
chromatograph used to separate analytes from each other and a mass spectrometer used 





1.2.1 High Pressure Liquid Chromatography 
High pressure liquid chromatography (HPLC) rapidly separates analytes from 
complex mixtures and matrices (8).  A high-pressure solvent delivery system utilizes a 
pump to inject the sample through an analytical column packed with small diameter 
porous particles.  The physical properties, such as pore size, and the chemistry of the 
stationary phase impacts the retention and separation of target analytes.  The stationary 
phase particles are coated in a chemically bonded phase that interacts with the sample.  A 
binary pump delivers high pressure mobile phase consisting of an aqueous portion and an 
organic portion.  The composition of the total mobile phase can change over the course of 
the run (gradient elution) or remain constant (isocratic elution).  Based on the strength of 
each analyte’s affinity for the stationary phase in the column, the analytes remain on the 
column until mobile phase conditions become more favorable.  Selecting the proper 
analytical column and mobile phase conditions is critical for achieving meaningful 
separation of the target analytes.  Consideration should be given to the functional groups 
available for interaction and differentiation of a method’s target analytes.  Ultimately the 
analytes are separated, ideally eluting at a unique time before undergoing electrospray 
ionization (8).  While many co-eluting analytes can be differentiated according to mass 
and fragmentation patterns, separation of compounds with identical parent masses and 





1.2.2 Electrospray Ionization 
The mass spectrometer requires gaseous charged ions for detection.  Electrospray 
ionization (ESI) is one way to vaporize and charge a sample so it can be analyzed by the 
MS (9).  Electrospray ionization begins as the eluent from the LC column flows through a 
metal capillary and where it is nebulized.  A potential difference imparts electrical charge 
on the droplets.  Heated drying gas de-solvates the droplets, increasing the charge density 
of the droplets.  Once the electric repulsion of the charged droplet exceeds the surface 
tension, Coulombic fission occurs forming gas phase ions.  As a soft ionization method, 
ESI results in protonated or de-protonated ions with little to no fragmentation.  Using a 
soft ionization method allows for sensitive detection of the parent ion.  Drawbacks to 
using ESI include ion suppression or enhancement from co-eluting analytes or matrix and 
the potential for ions with multiple charges (9).    
1.2.3 Mass Spectrometry 
Mass spectrometry separates and ionized gaseous ions based on their mass-to-
charge (m/z) (8).  While there are several different types of mass analyzers, one of the 
most common for quantitation is a triple quadrupole mass spectrometer (MS).  The triple 
quadrupole MS is a tandem in space spectrometer that allows for the selection and 
fragmentation of a precursor ion and detection of the product ion(s) produced.  Gas phase 
ions enter the mass analyzer through the sampling orifice.  The ions follow an ion guide 
to enter the first mass analyzer which uses electrostatic fields to deflect ions according to 





cell, where the precursor ion is fragmented via the introduction of a collision gas.  
Fragmentation is utilized to provide information about the chemical structure of the 
parent ion.  Certain bonds break more readily than others, resulting in a characteristic 
fragmentation pattern based on the physio-chemistry of the parent ion. The third 
quadrupole acts as a fragment mass filter using electrostatic fields to deflect the selected 
fragment ions to the detector.  At the detector, a current signal is generated based on the 
abundance of incident ions.  Converting that signal intensity concentration requires a 
known relationship current signal intensity and ion concentration that is often established 
with a calibration curve.  Because the response of the detector can fluctuate based on 
several variables, an internal standard experiencing identical conditions should be used to 
accurately convert signal intensity to a concentration value (10). Because the instrument 
selects for a specific parent mass in the first quadrupole and further selects for 
characteristic fragment masses selected in the third quadrupole, confident identification 
and quantification can be performed.  
1.2.4 Advantages 
LC-MS is advantageous over other methods in its combination of selectivity, 
sensitivity, and efficiency (11).  The combination of two selective techniques allows 
analytes in highly complex mixtures to be separated and analyzed.  LC separates 
compounds according to physicochemical properties while MS differentiates compounds 
according to their mass to charge ratio.  Analytes that may interact similarly with the 





and subsequent unique fragment ions (the precursor ion, the quantifier ion, and the 
qualifier ion).   
LC-MS analysis facilitates chromatographic resolution of isobaric species, or 
species with the same precursor ions.  Samples with different masses can coelute and be 
differentiated in the mass spectrometer.  Because coelution is acceptable, methods can 
have a much shorter run time.  Many analytes are large, non-volatile, or thermally 
unstable thus they require derivatization to be compatible with small, thermally labile, 
and volatile GC-MS method requirements.  LC-MS methods have been developed to 
forgo derivatization, decreasing sample preparation time (12).       
1.2.5 Disadvantages 
Optimization of LC-MS methods can be challenging given the “complex co-
dependent synergy” between the two (11).  LC-MS can have a limited range where the 
detector signal is linear in response to concentration, known as the dynamic range.  An 
important aspect of developing an LC-MS method is determining the linear range. Often 
the range of concentrations should not exceed 500-fold  (11).  LC-MS methods, 
especially those utilizing ESI, are impacted by ion suppression and enhancement effects 





1.3 LC-MS Method Development Considerations 
Method development is guided by information from four main categories: 
industry guidelines, analyte structure and chemical properties, matrix considerations, and 
previously developed methods (11).  
1.3.1 Industry Guidelines 
The American Academy of Forensic Science Standards Board (ASB) is a standard 
developing organization for forensic sciences accredited by the American National 
Standards Institute (13).  Recognizing the critical nature of toxicological testing in drug-
facilitated crimes, ASB standardized the analytical scope and sensitivity for toxicological 
examination of urine in DFSA cases (14).  The Toxicology Subcommittee of the 
Organization of Scientific Area Committees for Forensic Science examined the 
availability and prevalence of drugs in the United States, as well as the recommendations 
of the Society of Forensic Toxicologists (SOFT), a global toxicology organization (15).  
The SOFT DFSA committee published a list of 100 commonly encountered DFSA drugs, 
their target analytes, and the recommended minimum performance limit for analytical 
urine testing (16).  Flunitrazepam, commonly known as Rohypnol, was excluded from 
ASB 121 because several comprehensive case reviews of DFSA in the United States have 
found that it is infrequently detected due to its limited availability (6).   
 
Table 1. Required Minimum Analytical Scope and Sensitivity for Testing of Urine in Drug 
Facilitated Crime Investigations (14). 
Analyte Drug Class  
Minimum Required 
Sensitivity 





Analyte Drug Class  
Minimum Required 
Sensitivity 
7-aminoclonazepam Benzodiazepine 5 ng/mL 
Amitriptyline Antidepressant 10 ng/mL 
Amphetamine CNS Stimulant 25 ng/mL 
Benzoylecgonine CNS Stimulant 50 ng/mL 
Brompheniramine Antihistamine 10 ng/mL 
Butalbital Barbiturate 100 ng/mL 
Carisoprodol Miscellaneous 100 ng/mL 
Chlorpheniramine Antihistamine 10 ng/mL 
Codeine Opioid 10 ng/mL 
Cyclobenzaprine Miscellaneous 10 ng/mL 
Desipramine Antidepressant 10 ng/mL 
Dextromethorphan Miscellaneous 10 ng/mL 
Diphenhydramine Antihistamine 10 ng/mL 
Doxylamine Antihistamine 10 ng/mL 
Ethanol High-Dose Sedative 0.01 g/dL 
Fentanyl Opioid 1 ng/mL 
Gamma hydroxybutyrate (GHB) High-Dose Sedative 10 µg/mL  
Hydrocodone Opioid 10 ng/mL 
Hydromorphone Opioid 10 ng/mL 
Imipramine Antidepressant 10 ng/mL 
Lorazepam Benzodiazepine 5 ng/mL 
Meta-chlorophenylpiperazine (mCPP) Antidepressant 10 ng/mL 
Methylenedioxyamphetamine (MDA) CNS Stimulant 25 ng/mL 
Methylenedioxymethamphetamine (MDMA) CNS Stimulant 25 ng/mL 
Meprobamate Miscellaneous 100 ng/mL 
Methamphetamine CNS Stimulant 25 ng/mL 
Morphine Opioid 10 ng/mL 
Norchlorcylizine Antihistamine 10 ng/mL 
Nordiazepam Benzodiazepine 10 ng/mL 
Norfentanyl Opioid 1 ng/mL 
Norketamine Miscellaneous 10 ng/mL 
Nortriptyline Antidepressant 10 ng/mL 
Oxazepam Benzodiazepine 10 ng/mL 
Oxycodone Opioid 10 ng/mL 
Oxymorphone Opioid 10 ng/mL 
Phenobarbital Barbiturate 100 ng/mL 
Temazepam Benzodiazepine 10 ng/mL 
Carboxy-tetrahydrocannabinol (THCCOOH) Cannabinoid 10 ng/mL 
Tramadol Opioid 10 ng/mL 
Zolpidem carboxylic acid (COOH) Miscellaneous 10 ng/mL 










Figure 1.  Molecular Structure of Antidepressant Analytes 
Antidepressant drugs are most commonly prescribed for depression management 
but can also be used to treat anxiety, migraines or sleep disorders (17).  Tricyclic 
antidepressants consist of three hydrocarbon rings with a central alkylamine chain (18).  
Amitriptyline and imipramine are tertiary amine tricyclic antidepressants, while 





Their pKa values range from 9.4 to 10.3.  In the body, antidepressants work by inhibiting 
the reuptake of both serotonin and norepinephrine leading to higher levels of serotonin 
and norepinephrine available and an elevated mood, but can cause sedation depending on 
dose size and tolerance levels (19).  Trazadone’s major urinary metabolite is mCPP.  It is 
a centrally active 1-arylpiperazine that promotes serotonin release.  Upon ingestion, 
mCPP can produce euphorigenic effects similar to alcohol (20). 
1.3.2.2 Antihistamine 
Antihistamines are typically used to treat allergy symptoms.  Brompheniramine, 
chlorpheniramine, diphenhydramine, doxylamine, and chlorcyclizine are first generation 
antihistamines that are available over the counter and can cause extreme sedation (21).    
The drugs function in the body to block histamine binding at H1-receptors (22).  
Alkylamine H1-receptor agonists cause significant sedative action.  As a class, the drugs 
are lipophilic thus are readily able to cross the blood brain barrier (22). The major urinary 
metabolite of chlorcyclizine is norchlorcyclizine.  The chemical structure of 






Figure 2.  Molecular Structure of Antihistamine Analytes 
1.3.2.3 Barbiturate 
Barbiturates are derived from 5,5-di-substituted barbituric acid and act as a central 
nervous system depressant (23).  Barbiturates can produce a dose dependent range effects 
from mild sedation to complete anesthesia (24).  While they were previously prescribed 
therapeutically as antiepileptic drugs or sedatives, they have been largely replaced by 
benzodiazepines (25).  Barbiturates ionize more readily in negative-ESI, with the 4-






Figure 3.  Molecular Structures of Barbiturate Analytes 
1.3.2.4 Benzodiazepines 
Benzodiazepines are central nervous system depressants that are prescribed for sleep aid, 
anxiety management, or seizure prevention (26).  The relaxing and sedative effects of 
benzodiazepines have led to their increased use in drug facilitated crimes (27).  
Benzodiazepines can be consumed as capsules, tablets, or via injection.  Specific effects 
of benzodiazepine ingestion include confusion, memory loss, drowsiness, impaired 
coordination, and dizziness.  Benzodiazepines have a shared chemical structure of a fused 
benzene and diazepine ring with an attached phenyl ring (26).  They are lipophilic, and 
thus less soluble in ethanol and water (28).    The chemical structures of benzodiazepine 






Figure 4.  Molecular Structures of Benzodiazepine Analytes. 
1.3.2.5 Cannabinoids 
Cannabis sativa is a plant commonly referred to as marijuana and contains a 
family of drugs referred to as cannabinoids.  Marijuana’s major urinary metabolite is 11-
nor-Δ9-tetrahydrocannabinol-9-carboxylic acid, or THCCOOH and its glucuronide ester 
(29).  Unbound THCCOOH has a pKa of 4.4.  THCCOOH decarboxylates to its 
corresponding phenol over time, under alkaline conditions, or upon heating.  Upon 
intake, cannabis acts as a central nervous system depressant and can induce physiological 





its psychoactive properties, marijuana has been used to treat pain, nausea, asthma, 




Figure 5. Molecular Structure of Cannabinoid Analyte 
1.3.2.6 Stimulants 
Stimulants are commonly encountered in DFSA because they lower inhibition, 
increase susceptibility to suggestion, and can increase sex drive (28).  Stimulants are 
often mixed with central nervous system depressants to enhance the high or compensate 
for undesired side effects (30).  Cocaine quickly metabolizes to its main urinary 
metabolite, benzoylecgonine which is used as a target analyte for toxicological analysis 
(31).  While cocaine has historically been used medicinally as a local anesthetic, it has 
been replaced by safer alternatives and is now mainly encountered in recreational use 
(32).  MDA and MDMA are ring-substituted amphetamine analogues with psychotropic 





be prescribed for attention deficit disorder management but are often diverted or 
synthesized for recreational use (32). 
 
Figure 6. Molecular Structures of Stimulant Analytes. 
1.3.2.7 Opioids 
Opioids are natural alkaloids derived from opium poppy resin and their semi-synthetic 
and synthetic counterparts.  They are often prescribed to treat acute pain or relieve 
moderate chronic pain.  Opioid intake can cause dizziness, fatigue, sedation, confusion 
and blurred vision.  Opioids are extensively glucuronidated in urine (33).  They are 
typically weak bases with pKa values ranging from 8 to 10 (34).  The molecular 






Figure 7.  Molecular Structures of Opioid Analytes. 
1.3.2.8 Miscellaneous 
The last group of analytes include drugs that do not neatly fit into the other 
classes but have similar sedating effects.  Dextromethorphan is an antitussive found in 
over the counter cough suppressants.  In high doses, dextromethorphan can produce 





drugs” and are prescribed as sleep aids.  Zolpidem’s major urinary metabolite zolpidem 
carboxylic acid.  Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, 
can cause psychotomimetic and dissociative effects.  Norketamine is the major urinary 
metabolite of ketamine (36).  Carisoprodol and meprobamate are muscle relaxants.  
Meprobamate is a metabolite of carisoprodol but can exist as its own pharmaceutical 
preparation (37).  The molecular structures of the miscellaneous analytes are depicted in 
Figure 8.  Ethanol and GHB are high dose sedatives, requiring higher doses than the other 
drugs discussed induce memory loss and sedative effects.  Ethanol is the most commonly 
encountered substance in DFSA cases and can cause unconsciousness and memory 
disruption in high doses (38).  GHB has memory-impairing effects, induces strong 






Figure 8. Molecular Structures of Miscellaneous Analytes 
1.3.3 Information about the type and condition of sample that will be measured 
Urine is a typical sample of choice in DFSA cases, as it may extend the window 
of drug detection up to 120 hours (5 days) after the alleged incident (40). Urine provides 
a longer detection window than blood.  In one study, 9.3% of 155 cases where both blood 
and urine were collected, at least one substance was detected in urine but not in blood (6).  





substances such as benzodiazepines, marijuana, or cocaine may be detectable in urine 
while no longer contributing to intoxication (41).  When developing analytical methods 
for urine, it is important to consider whether the drug of interest will be present in urine 
and if species of similar mass to charge ratio as the targeted will interfere with analysis.   
The drug may undergo significant metabolism such that there will be little to no 
unchanged drug present in urine.  For example, less than 1% of a zolpidem dose is 
detectable as unchanged drug in urine (42).  Thus it is important that urine analysis target 
the major urinary metabolite, zolpidem 4-phenyl carboxylic acid which represents 33-
48% of an ingested Zolpidem dose depending on pharmacokinetic dynamics (42).   
Drugs are excreted in urine in free-base and glucuronidated forms.  The percent of 
drugs in glucuronidated form varies by class, however benzodiazepines, opiates, and 
THCCOOH have been found to exhibit high levels of glucuronidation (43).  Hydrolysis, 
whether chemical or enzymatic, can be performed during sample preparation to allow more 
drug to be available in free base form for examination.   
 
1.3.4 Previously developed methods 
 Many current analytical approaches for suspected DFSA samples involve several 
methodologies and instrumentation types.  For example, the Victorian Institute of Forensic 
Medicine performs analysis on DFSA urine samples as follows: alcohol testing via gas 
chromatography (GC), an immunoassay screen for amphetamines, benzodiazepines, 
cannabis, cocaine, and opiates, a liquid GC-MS screen for basic and neutral drugs, a 





of GHB with a 10 mg/L cut-off (44).    In 2007, Feng et al developed one of the first LC-
MS/MS methods for quantitative analysis of 30 drugs from multiple classes including 
opioids, barbiturates, stimulants, cannabinoids, and benzodiazepines (45).  Their method, 
however, involved a separate positive and negative mode analysis with different LC 
gradients and MS parameters.  Simultaneous quantitation of 78 drugs via LC-MS with a 
dilute-and-shoot sample preparation has been developed, but again with separate positive 
and negative mode LC gradients and MS parameters (46).  Ultra-performance (UP) LC-
MS methods utilizing positive and negative ESI mode have been successfully validated for 
the analysis of several drug classes simultaneously in equine urine, including all of the 
benzodiazepine and barbiturate analytes included in ASB 121 (47).   
Immunoassays are commonly used as a screening tool for toxicology samples, but 
require confirmation by other methods, and typically have a limited range of substances.  
Additionally, many commercial immunoassays do not have the requisite sensitivity to 
reliably detect the low drugs levels common in DFSA cases (40).  The analytical methods 
currently available do not meet the scope of drugs outlined in ASB 121.  The aim of the 
presented research was the development and validation of a LC-MS/MS quantitative assay 








2. MATERIALS AND METHODS 
2.1 Chemicals, Reagents, and Standards 
All certified reference standards and isotope-labeled internal standard solutions 
were purchased from Cerilliant (Round Rock, TX, USA), Cayman Chemical Company 
(Ann Arbor, MI, USA) or Lipomed (Cambridge, MA, USA).  Methanol (Optima LC/MS 
grade), ethyl acetate, ammonium hydroxide, and ammonium formate were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA).  Formic acid (LC/MS grade, 98%) was purchased 
from Sigma-Aldrich (St Louis, MO, USA).  Deionized water was generated with a Milli-
Q water purification system from Millipore (Billerica, MA, USA).  Drug-free urine was 
obtained via donations approved by Institutional Review Board (IRB) requirements at 
Boston University School of Medicine (Boston, MA, USA).   
2.2 Instrumentation  
2.2.1 Liquid Chromatography 
Analysis was performed with a QSight® LX50 UHPLC system consisting of two 
UHPLC pumps, an autosampler, and a column oven from PerkinElmer (Waltham, MA, 
USA).  Chromatographic separation was achieved with a 50 x 4.6 mm, pore size 100 Å, 
2.6 µm core-shell Kinetex® phenyl-hexyl HPLC column from Phenomenex® (Torrance, 
CA, USA).  The column was kept at 40 °C for the entirety of the method.  The aqueous 
mobile phase A was 0.1% formic acid in Millipore water and the organic mobile phase B 
was 0.1% formic acid in methanol.  The flow rate was 0.6 mL/min with a maximum 





elution (Table 2).  A Rheodyne® diverter valve (Rohnert Park, CA, USA) was used to 
direct sample from the column to the mass spectrometer between 2-9 min.  All other eluent 
off the column was directed to waste to minimize contamination of the MS.     
Table 2. LC Gradient Time Program. 
Time (min) Flow (mL/min) %A %B 
 0.00 0.600 95 5 
0.50 0.600 95 5 
2.50 0.600 85 15 
6.00 0.600 50 50 
7.00 0.600 5 95 
9.00 0.600 5 95 
10.00 0.600 95 5 
11.00 0.600 95 5 
 
The samples were kept at 5°C in the autosampler to prevent sample degradation and 
sampled at a 10 μL injection volume.  The autosampler needle was washed with a 250 μL 
weak wash of 50% (v/v) aqueous methanol, then a 250 μL strong wash of 90% (v/v) 
aqueous methanol, then a final 250 μL weak wash to prevent carryover in between sample 
injections.     
2.2.2 Mass Spectrometry 
Analytes were detected using a QSight® 220 series triple quadrupole MS detector 
with ESI source, HSID™ interface, and UniField Detector™.  Data collection, analysis, 
and quantification was performed using Simplicity 3QTM software (PerkinElmer). 
Analytes were detected by mass spectrometry using time-managed multiple 





identifying fragment ions were determined via compound optimization using purified 
standards to find the optimum signal for the entrance voltage (EV), collision cell energy 
(CC) and collision cell lens 2 voltage (CCL2).  Experiments utilizing MRM allow for 
targeted analyte detection by allowing the first MS to transmit ions with the precursor ion 
m/z to the collision cell.  After being fragmented with Nitrogen gas, the second quadrupole 
allowed transmission of all product ions to the third quadrupole, where only the products 
of interest were selected to be monitored by the detector.   
Table 3. Optimized Source Conditions. 
Drying Gas HSID 
Temperature 
Nebulizer Gas Electrospray V1 Source 1 
Temperature 
100 250°C 150 5500 500°C 
2.3 Method Development 
2.3.1 Compound Optimization 
Optimized MRM transitions for each analyte were determined by directly infusing 
certified reference standards diluted to 100 ng/mL in 50% aqueous methanol fortified with 
0.1% formic acid into the mass spectrometer at a flow rate of 30 μL/min.  The precursor 
ion mass was determined by performing an MS full scan.  Next, a product ion scan was 
performed of the precursor ion while the collision energy (CC) was ramped from -200 to 
zero.  Two product ions were selected based foremost on intensity, but considerations for 
avoiding isobaric transitions and low background noise in urine were also considered.  
Adducts were avoided per the ASB Standard for Mass Spectral Data Acceptance in 





MRM transition was defined as the quantifier, and the lesser abundant defined as the 
qualifier.  For internal standards, only one MRM transition was monitored.  Entrance 
voltage (EV), CCL2 (collision cell lens 2), and collision energy (CC) were determined for 
each MRM transition (Table 4) using the automatic optimization feature of the instrument 
software. 
Table 4. Optimized MRM Parameters. 
Analyte Q1 m/z Q2 m/z CC EV CCL2 Polarity 
α-hydroxyalprazolam 325.1 297 -33 32 -76 + 
α-hydroxyalprazolam 325.1 216.1 -33 38 -320 + 
α-hydroxyalprazolam-d5 330 302.2 -33 19 -96 + 
7-aminoclonazepam 286.21 121.1 -34 23 -100 + 
7-aminoclonazepam 286.21 222.2 -34 29 -76 + 
7-aminoclonazepam-d4 290.8 121.2 -34 16 -108 + 
Amitriptyline 278.3 202.3 -81 26 -160 + 
Amitriptyline 278.3 191.1 -81 26 -160 + 
Amitriptyline-d3 281.1 202.1 -81 26 -160 + 
Amphetamine 136 119 -11 15 -24 + 
Amphetamine 142.2 93.1 -46 10 -52 + 
Amphetamine-d6 136 91 -60 12 -45 + 
Benzoylecgonine 290.2 105.1 -28 0 -64 + 
Benzoylecgonine 290.2 168.1 -27 0 -56 + 
Benzoylecgonine-d8 298.2 171 -27 14 -60 + 
Brompheniramine 321.1 276.1 -32 22 -84 + 
Brompheniramine 321.1 167.1 -36 19 -220 + 
Butalbital 223.1 180 16 0 36 - 
Butalbital 223.1 42.2 16 0 44 - 
Butalbital-d5 228.1 41.9 15 0 52 - 
Carisoprodol 261.2 176 -13 10 -44 + 
Carisoprodol 261.2 55.3 -59 13 -64 + 
Carisprodol-d7 268.2 183.1 -13 10 -44 + 
Chlorpheniramine 275.1 167.1 -24 16 -316 + 
Chlorpheniramine 275.1 230.1 -24 1 -56 + 
Chlorpheniramine-d6 281.1 230.2 -23 4 -54 + 
Codeine 300.1 153 -52 33 -136 + 
Codeine 300.1 165 -52 30 -84 + 
Codeine-d6 306.1 165 -52 39 -112 + 
Cyclobenzaprine 276.2 215.1 -35 30 -68 + 





Analyte Q1 m/z Q2 m/z CC EV CCL2 Polarity 
Cyclobenzaprine-d3 279.1 191.1 -31 39 -60 + 
Desipramine 267.2 236 -21 0 -56 + 
Desipramine 267.2 72.1 -19 13 -48 + 
Desipramine-d3 270.2 75.3 -19 13 -48 + 
Dextromethorphan 275 213.2 -35 24 -92 + 
Dextromethorphan 272.2 147.1 -35 24 -76 + 
Dextromethorphan-d3 272.2 213.1 -35 24 -92 + 
Diphenhydramine 256.2 152.1 -70 14 -112 + 
Diphenhydramine 256.2 165.1 -70 13 -108 + 
Diphenhydramine-d3 259.1 165.1 -70 14 -112 + 
Doxylamine 271.2 182.1 -33 13 -64 + 
Doxylamine 271.2 167.1 -50 13 -108 + 
Doxylamine-d5 276.2 187.1 -50 13 -108 + 
Fentanyl 337.1 188.2 -33 30 -80 + 
Fentanyl 337.1 105.1 -53 30 -88 + 
Fentanyl-d5 342.5 79.2 -69 15 -68 + 
Hydrocodone 300.3 199.1 -34 43 -104 + 
Hydrocodone 300.3 171 -35 43 -288 + 
Hydrocodone-d3 303.3 199 -34 31 -100 + 
Hydromorphone 286.1 157 -37 0 -252 + 
Hydromorphone 286.1 185.1 -36 45 -112 + 
Hydromorphone-d6 292.2 185 -36 12 -112 + 
Imipramine 281.1 58.1 -23 25 -63 + 
Imipramine 281.1 86.1 -23 6 -52 + 
Imipramine-d3 284.2 89.1 -23 17 -58 + 
Lorazepam 321.1 275 -27 26 -76 + 
Lorazepam 321.1 229.1 -48 19 -116 + 
Lorazepam-d4 325 279.1 -24 9 -76 + 
mCPP 197.1 154.1 -26 27 -44 + 
mCPP 197.1 91 -51 18 -72 + 
mCPP-d8 205.1 158.1 -35 33 -52 + 
MDA 180.2 163.1 -15 2 -40 + 
MDA 180.2 105.1 -41 3 -64 + 
MDA-d5 185.1 168 -15 5 -36 + 
MDMA 194.2 163.2 -16 16 -36 + 
MDMA 194.2 105 -44 13 -68 + 
MDMA-d5 199.1 165.2 -17 16 -36 + 
Meprobamate 219.2 97.1 -22 15 -43 + 
Meprobamate 219.2 158.3 -13 1 -35 + 
Meprobamate-d3 222 161.3 -13 1 -35 + 
Methamphetamine 150 119.1 -16 18 -28 + 
Methamphetamine 150 91 -32 17 -36 + 





Analyte Q1 m/z Q2 m/z CC EV CCL2 Polarity 
Morphine 286.1 153 -51 0 -104 + 
Morphine 286.1 181.1 -50 15 -100 + 
Morphine-d6 292.1 181 -50 21 -120 + 
Norchlorcyclizine 287.1 166.1 -36 7 -228 + 
Norchlorcyclizine 287.1 201.1 -25 9 -36 + 
Nordiazepam 271 165 -35 22 -88 + 
Nordiazepam 271.1 140 -34 18 -76 + 
Nordiazepam-d5 276.1 140 -34 5 -72 + 
Norfentanyl 233.2 177.1 -18 5 -48 + 
Norfentanyl 233.2 84.1 -18 22 -44 + 
Norfentanyl-d5 238.2 84.1 -18 28 -48 + 
Norketamine 224 125 -13 19 -350 + 
Norketamine 224 207.1 -14 16 -44 + 
Norketamine-d4 228.2 129 -13 19 -350 + 
Nortriptyline 264.1 117 -32 1 -60 + 
Nortriptyline 264.1 233.2 -17 11 -60 + 
Nortriptyline-d3 267.2 191.1 -32 1 -60 + 
Oxazepam 287.2 269.1 -24 11 -60 + 
Oxazepam 287.2 241.1 -24 34 -68 + 
Oxazepam-d5 292.2 246.2 -24 36 -80 + 
Oxycodone 316.2 298.2 -20 0 -64 + 
Oxycodone 316.2 241.2 -33 27 -104 + 
Oxycodone-d6 322.1 304.1 -20 18 -68 + 
Oxymorphone 302.1 284.2 -23 0 -76 + 
Oxymorphone 302.1 227.1 -24 0 -112 + 
Oxymorphone-d3 305.1 287.1 -22 3 -76 + 
Phenobarbital 231 188 14 -21 44 - 
Phenobarbital 231 42.1 15 -11 48 - 
Phenobarbital-d5 236.1 42.2 15 -11 44 - 
Temazepam 301.2 255.2 -30 25 -72 + 
Temazepam 301.2 283.1 -19 27 -52 + 
Temazepam-d5 306.1 260 -27 9 -84 + 
THCCOOH 343.2 245.2 34 -35 164 - 
THCCOOH 343.2 191.2 51 -34 156 - 
THCCOOH-d3 346.3 194.1 49 -21 104 - 
Tramadol 264.32 58 -15 16 -48 + 
Tramadol 264.32 264.32 -14 11 -56 + 
Tramadol-d3 268.2 58.3 -15 24 -44 + 
Zolpidem COOH 338.1 293.2 -43 34 -72 + 
Zolpidem COOH 338.1 265.1 -47 42 -104 + 
Zolpidem COOH-d4 342.1 269.2 -47 42 -104 + 
Zopiclone 389 217.1 -49 1 -68 + 





Analyte Q1 m/z Q2 m/z CC EV CCL2 Polarity 
Zopiclone-d4 393.2 245.1 -49 1 -68 + 
  
2.3.2 Sample preparation 
Calibrators and quality control samples were prepared by spiking certified 
reference material for each analyte at the desired concentration in analyte-free human 
urine.  Samples were additionally fortified, where appropriate, with each analyte’s stable 
isotope internal standard to a final concentration of 150 ng/mL.       
Dilute-and-shoot sample preparation was evaluated by transferring 100 μL of 
sample to a glass vial and centrifuging for 3 minutes at 10,000 revolutions per minute in 
an Eppendorf 5430 centrifuge (Enfield, CT, US).  Sample supernatant was transferred to 
an LC vial and diluted with starting phase mobile conditions (95% A: 5% B) referred to 
as diluent. Three different supernatant-to-diluent ratio preparations were evaluated: 10 μL 
supernatant with 990 μL diluent; 10 μL supernatant with 490 μL diluent; and 50 μL 
supernatant with 150 μL diluent.   
Supported liquid extraction (SLE) sample preparation was evaluated by mixing 
250 μL of fortified urine samples in a disposable glass vial with 250 μL of 0.5 
ammonium hydroxide and 75 μL of ICSMSzymeTM RT with buffer solution.  The 
samples were gently vortexed and incubated at room temperature for 15 minutes.  After 
incubation, 400 μL of each sample was transferred to an individual Biotage Isolute® 
SLE+ (Salem, NH, USA) column and allowed to absorb for 5 minutes.  Two separate 2 
mL ethyl acetate elutions were performed, allowing 5 minutes after each wash for 





eluent was completely evaporated under nitrogen gas at 40°C and the sample was 
reconstituted in 100 μL of starting mobile phase conditions.  The entire sample was 
transferred to an LC vial with a flat-bottomed liner for analysis.     
2.4 Method Validation 
The final method was validated for quantitation by assessing linearity, calibration 
model, limit of detection (LOD), lower limit of quantitation (LLOQ), bias, precision, carry 
over, interference, and ionization suppression or enhancement effects per the ASB 
Standard Practices for Method Validation in Forensic Toxicology, which delineates 
minimum requirements for validating analytical methods in forensic toxicology  (49).  As 
an additional measure, recovery was evaluated.  Per ASB 036, the validation could have 
been limited to carryover, interference, limit of detection, and ionization suppression or 
enhancement if the method were to be used only qualitatively.          
2.4.1 Analyte identification criteria 
An analyte was considered identified if the retention time of an analyte was 
within ±2% of its corresponding deuterated internal standard with acceptable diagnostic 
ratios.  Diagnostic ion ratios were required to agree with the ratios calculated from the 
reference material within 20% if the relative abundance was greater than 50%, within 
25% if the relative abundance was between 20 and 50%, and within 30% if the relative 





2.4.2 Calibration Model 
Calibrator (Cal) samples of eight different concentrations were used to determine 
the working range of the method.  Calibrators were prepared in a one stock methanol 
solution based on a percentage of the minimum required sensitivity for each analyte as 
follows: 50% (Cal 1), 100% (Cal 2), 300% (Cal 3), 500% (Cal 4), 700% (Cal 5), 1000% 
(Cal 6), 1500% (Cal7), and 2000% (Cal 8).  The calibration model was established over 
five separate runs by plotting the ratio of the peak area of the analyte to the peak area of its 
internal standard against the known concentration at each calibrator concentration.  
Calibration curves with a correlation coefficient (R2) of .980 or better were deemed 
acceptable.   
  


















α-hydroxyalprazolam 2.5 5 15 25 35 50 75 100 
7-aminoclonazepam 2.5 5 15 25 35 50 75 100 
Amitriptyline 5 10 30 50 70 100 150 200 
Amphetamine 12.5 25 75 125 175 250 375 500 
Benzoylecgonine 25 50 150 250 350 500 750 1000 
Brompheniramine 5 10 30 50 70 100 150 200 
Butalbital 50 100 300 500 700 1000 1500 2000 
Carisoprodol 50 100 300 500 700 1000 1500 2000 
Chlorpheniramine 5 10 30 50 70 100 150 200 
Codeine 5 10 30 50 70 100 150 200 
Cyclobenzaprine 5 10 30 50 70 100 150 200 
Desipramine 5 10 30 50 70 100 150 200 
Dextromethorphan 5 10 30 50 70 100 150 200 
Diphenhydramine 5 10 30 50 70 100 150 200 
Doxylamine 5 10 30 50 70 100 150 200 
Fentanyl 0.5 1 3 5 7 10 15 20 
Hydrocodone 5 10 30 50 70 100 150 200 
Hydromorphone 5 10 30 50 70 100 150 200 






















Lorazepam 2.5 5 15 25 35 50 75 100 
mCPP 5 10 30 50 70 100 150 200 
MDA 12.5 25 75 125 175 250 375 500 
MDMA 12.5 25 75 125 175 250 375 500 
Meprobamate 50 100 300 500 700 1000 1500 2000 
Methamphetamine 12.5 25 75 125 175 250 375 500 
Morphine 5 10 30 50 70 100 150 200 
Norchlorcyclizine 5 10 30 50 70 100 150 200 
Nordiazepam 5 10 30 50 70 100 150 200 
Norfentanyl 0.5 1 3 5 7 10 15 20 
Norketamine 5 10 30 50 70 100 150 200 
Nortriptyline 5 10 30 50 70 100 150 200 
Oxazepam 5 10 30 50 70 100 150 200 
Oxycodone 5 10 30 50 70 100 150 200 
Oxymorphone 5 10 30 50 70 100 150 200 
Phenobarbital 50 100 300 500 700 1000 1500 2000 
Temazepam 5 10 30 50 70 100 150 200 
THCCOOH 5 10 30 50 70 100 150 200 
Tramadol 5 10 30 50 70 100 150 200 
Zolpidem COOH 5 10 30 50 70 100 150 200 
Zopiclone 5 10 30 50 70 100 150 200 
 
2.4.3 Limit of Detection 
The LOD was estimated for each analyte by calculating the standard deviation of 
the y intercept (sy) and the average slope (Avgm) from 3 independent calibration curves 
across the working range of the method.  In addition to the eight calibrators prepared 
earlier, three additional calibrators were added at concentrations of 25%, 12.5%, and 
6.125% of the minimum required sensitivity.  The estimation of the LOD according to 
Equation 4 has been found to be more realistic than using three times the signal-to-noise 
ratio (50). 
𝐿𝑂𝐷 =  (3.3 𝑠𝑦) 𝐴𝑣𝑔𝑚⁄   
 





2.4.4 Lower Limit of Quantitation 
The lowest non-zero calibrator (Cal 1) was used to estimate the LLOQ.  Three 
analyte-free urine samples from different sources were fortified with each analyte at 50% 
of the minimum required sensitivity and analyzed for detection, identification, bias, and 
precision.  If the samples were within ±20% accuracy, Cal 1 was an acceptable estimated 
LLOQ.   
2.4.5 Bias 
Bias was measured in pooled fortified urine using quality control samples at 200% 
(low), 600% (medium), and 1200% (high) the minimum required sensitivity.  All samples 
used for bias calculations fell within the working range for each analyte evaluated.  Each 
concentration was analyzed in triplicate over five different runs.  Bias was calculated via 
Equation 1, with a maximum acceptable bias of ±20%.  
𝐵𝑖𝑎𝑠 (%)𝑎𝑡 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥 = [
𝐺𝑟𝑎𝑛𝑑 𝑀𝑒𝑎𝑛 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥−𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥 
𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥 
] × 100  
 
Equation 2.  Bias calculation. 
2.4.6 Precision 
Intra- and inter-run precision were measured concurrently with bias utilizing the 
three quality control sample concentrations.  Intra-run precision was calculated for each of 
the five runs at the three different concentrations via Equation 2.  Inter-run precision was 
calculated at low, medium, and high concentration via Equation 3.  A grand mean precision 
was calculated by averaging the inter- and intra-run precisions.   
𝐼𝑛𝑡𝑟𝑎 − 𝑟𝑢𝑛 𝐶𝑉(%) = [
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎 𝑟𝑢𝑛 
𝑚𝑒𝑎𝑛 𝑐𝑎𝑙𝑐𝑢𝑎𝑙𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑎 𝑟𝑢𝑛 






Equation 3.  Within-run precision calculation. 
 
𝐼𝑛𝑡𝑒𝑟 − 𝑟𝑢𝑛 𝐶𝑉(%) = [
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
𝑔𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛
] × 100  
 
Equation 4.  Between-run precision calculation. 
 
2.4.7 Carryover 
Carryover was evaluated by analyzing a blank urine sample following the highest 
calibrator for each analyte over five separate runs.  Carryover was deemed acceptable if 
signal intensity did not exceed 10% of the lowest calibrator signal.   
2.4.8 Interference 
 Matrix and internal standard interferences were evaluated.  Commonly 
encountered analyte interferences were not evaluated in this validation.   
2.4.8.1 Matrix Interferences 
Ten analyte-free urine samples were analyzed without the addition of an IS to 
determine if common matrix interferences were present.   Signal greater than the calculated 
limit of detection and within 2% of the known retention time were labeled as interferences. 
2.4.8.2 IS Interference 
Stable-isotope internal standard interference was assessed by analyzing an analyte-
free urine sample spiked with IS for each analyte and observing for analyte signal above 
the LOD.  Additionally, a urine sample fortified with 2000% of the minimum required 





signal.  Signal greater than the calculated limit of detection and within 2% of the known 
retention time were labeled as interferences.  
2.4.9 Ionization Suppression and Enhancement 
A sample of 100 μL of mobile phase at starting conditions (95% A and 5% B) 
containing 150 ng/mL of all internal standards and all analytes at 200% the minimum 
required sensitivity was prepared.  A similar sample was prepared with all analytes at 
1000% the minimum required sensitivity.  The neat samples were injected six times to 
obtain the average peak area of each analyte at high and low concentrations.   
Ten analyte-free urine samples from different sources were extracted via the SLE 
protocol.  After drying, the samples were reconstituted with starting condition mobile phase 
spiked with all analytes at 200% their minimum required sensitivities and 150 ng/mL of 
all internal standards.  An additional ten samples were prepared in the same manner and 
spiked with all analytes 1000% of their minimum required sensitivities.  The samples were 
run to obtain the average peak area of each analyte at high and low concentrations.  
The neat sample average peak area was compared to the urine sample average peak area at 
the corresponding concentration to calculate ion enhancement or suppression (Equation 5).  
Ion enhancement or suppression was deemed acceptable if it was within ±25%.    
𝐼𝑜𝑛 𝑆𝑢𝑝𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 (%) = (
𝑛𝑒𝑎𝑡 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
𝑢𝑟𝑖𝑛𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
− 1) × 100  






Analyte recovery was determined by comparing samples fortified post-extraction with 
samples fortified pre-extraction according to Equation 5.  10 pre-extraction and 10 post-
extraction samples were compared at low concentration (200% minimum required 
sensitivity) and high concentration (1200% minimum required sensitivity).   
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =
𝑝𝑟𝑒−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
𝑝𝑜𝑠𝑡−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
× 100  
Equation 6.  Recovery Calculation. 
3. RESULTS  
3.1 Analyte Detection 
Analytes eluted between 2 and 9 minutes (Figure 9). Morphine eluted first at 2.12 







Figure 9. Complete MRM chromatograph of all Analytes at Cal. 7 Concentration 
  Analytes were eluted in the following order: morphine, oxymorphone, hydromorphone, 
amphetamine, codeine, methamphetamine, MDA, oxycodone, hydrocodone, MDMA, doxylamine, 
norketamine, zolpidem COOH, norfentanyl, tramadol, 7-aminoclonazepam, m-CPP, benzoylecgonine, 
zopiclone, chlorpheniramine, meprobamate, brompheniramine, fentanyl, phenobarbital, dextromethorphan, 
butalbital, cyclobenzaprine, desipramine, imipramine, amitriptyline, nortriptyline, norchlorcyclizine, 
carisoprodol, lorazepam, α-hydroxyalprazolam, oxazepam, nordiazepam, temazepam, and THCCOOH. 
 
All analytes eluted within 2% of their corresponding stable isotope internal 
standard. Analytes not completely resolved via HPLC were easily distinguished by their 
distinctive MRM transitions.     
 





IS Retention Time 
(min) 
α-hydroxyalprazolam 7.19 α-hydroxalprazolam-d5 7.17 
7-aminoclonazepam 5.33 7-aminoclonazepam-d4 5.28 
Amitriptyline 6.65 Amitriptyline-d3 6.63 









IS Retention Time 
(min) 
Benzoylecgonine 5.33 Benzoylecgonine-d8 5.30 
Brompheniramine 5.94 Chlorpheniramine-d6 5.74 
Butalbital 6.36 Butalbital-d5 6.33 
Carisoprodol 6.83 Carisprodol-d7 6.83 
Chlorpheniramine 5.74 Chlorpheniramine-d6 5.74 
Codeine 3.61 Codeine-d6 3.55 
Cyclobenzaprine 6.53 Cyclobenzaprine-d3 6.53 
Desipramine 6.56 Desipramine-d3 6.56 
Dextromethorphan 6.12 Dextromethorphan-d3 6.12 
Diphenhydramine 6.08 Diphenhydramine-d3 6.08 
Doxylamine 4.46 Doxylamine-d5 4.36 
Fentanyl 6.06 Fentanyl-d5 6.06 
Hydrocodone 4.09 Hydrocodone-d3 4.08 
Hydromorphone 2.62 Hydromorphone-d6 2.60 
Imipramine 6.56 Imipramine-d3 6.56 
Lorazepam 7.12 Lorazepam-d4 7.12 
mCPP 5.26 mCPP-d8 5.22 
MDA 3.61 MDA-d5 3.58 
MDMA 4.01 MDMA-d5 3.97 
Meprobamate 5.94 Meprobamate-d3 5.94 
Methamphetamine 3.61 Methamphetamine-d5 3.58 
Morphine 2.12 Morphine-d6 2.12 
Norchlorcyclizine 6.70 Amitriptyline-d3 6.63 
Nordiazepam 7.38 Nordiazepam-d5 7.35 
Norfentanyl 4.91 Norfentanyl-d5 4.88 
Norketamine 4.74 Norketamine-d4 4.71 
Nortriptyline 6.63 Nortriptyline-d3 6.63 
Oxazepam 7.20 Oxazepam-d5 7.19 
Oxycodone 3.93 Oxycodone-d6 3.89 
Oxymorphone 2.37 Oxymorphone-d3 2.35 
Phenobarbital 6.03 Phenobarbital-d5 6.00 
Temazepam 7.43 Temazepam-d5 7.40 
THCCOOH 8.15 THCCOOH-d3 8.14 
Tramadol 5.12 Tramadol-d3 5.10 
Zolpidem COOH 4.84 Zolpidem COOH 4.83 







3.2 Method Validation  
3.2.1 Calibration Model, LOD, and LLOQ 
Linearity was determined using the ratio of the analyte peak area to the internal 
standard against the known concentration of standards by weighted linear regression (1/x).  
In this study, correlation coefficients at or above .98 were considered acceptable.  Most 
analytes displayed linearity with a correlation coefficient greater than .98Table A 12.  R 
squared Values for Calibration Model Runs.Table 7). Zopiclone and zolpidem COOH as well as 
their corresponding internal standards were not detected in any calibration samples.  
THCCOOH had an average correlation coefficient of .94, with a range of .906 to .991 
between the five runs analyzed (Table 7).  ASB 036 recommends the use of residual plots 
to assess the homoscedasticity of each analyte across the working range instead of relying 
on calibration coefficients.  The theoretical limit of detection was below the required 
minimum sensitivity for all analytes except THCCOOH.  The lower limit of quantitation 
was determined to be equal to 50% the minimum required sensitivity for all analytes accept 
doxylamine, dextromethorphan, brompheniramine, and norchlorcyclizine.  For these 
analytes, 100% the minimum required sensitivity was an acceptable lower limit of 
quantitation.  THCCOOH displayed a LLOQ of 200% the minimum required sensitivity.  











α-hydroxyalprazolam 2.5-100 ng/mL linear 0.989 1.37 2.5 
7-aminoclonazepam 2.5-100 ng/mL linear 0.993 4.84 2.5 
Amitriptyline 5-200 ng/mL linear 0.989 3.85 2.5 















Benzoylecgonine 25-1000 ng/mL linear 0.990 21.11 25 
Brompheniramine 5-200 ng/mL linear 0.993 4.63 10 
Butalbital 50-2000 ng/mL linear 0.990 27.40 50 
Carisoprodol 50-2000 ng/mL linear 0.994 18.29 50 
Chlorpheniramine 5-200 ng/mL linear 0.993 4.30 5 
Codeine 5-200 ng/mL linear 0.995 1.92 5 
Cyclobenzaprine 5-200 ng/mL linear 0.992 3.5 5 
Desipramine 5-200 ng/mL linear 0.994 2.56 5 
Dextromethorphan 5-200 ng/mL linear 0.996 2.47 10 
Diphenhydramine 5-200 ng/mL linear 0.992 2.75 5 
Doxylamine 5-200 ng/mL linear 0.993 6.85 10 
Fentanyl 0.5-20 ng/mL linear 0.995 0.392 0.5 
Hydrocodone 5-200 ng/mL linear 0.992 2.91 5 
Hydromorphone 5-200 ng/mL linear 0.993 3.10 5 
Imipramine 5-200 ng/mL linear 0.993 2.57 5 
Lorazepam 2.5-100 ng/mL linear 0.993 1.42 2.5 
mCPP 5-200 ng/mL linear 0.994 3.92 5 
MDA 12.5-500 ng/mL linear 0.995 11.5 12.5 
MDMA 12.5-500 ng/mL linear 0.994 5.09 12.5 
Meprobamate 50-2000 ng/mL linear 0.995 44.8 50 
Methamphetamine 12.5-500 ng/mL linear 0.994 5.25 12.5 
Morphine 5-200 ng/mL linear 0.995 3.31 5 
Norchlorcyclizine 5-200 ng/mL linear 0.987 7.35 10 
Nordiazepam 5-200 ng/mL linear 0.994 1.60 5 
Norfentanyl 0.5-20 ng/mL linear 0.995 .14 0.5 
Norketamine 5-200 ng/mL linear 0.993 4.22 5 
Nortriptyline 5-200 ng/mL linear 0.993 3.18 5 
Oxazepam 5-200 ng/mL linear 0.993 2.57 5 
Oxycodone 5-200 ng/mL linear 0.996 4.76 5 
Oxymorphone 5-200 ng/mL linear 0.995 4.93 5 
Phenobarbital 50-2000 ng/mL linear 0.990 17.77 50 
Temazepam 5-200 ng/mL linear 0.994 1.78 5 
THCCOOH 5-200 ng/mL linear 0.949 5 30 






3.2.2 Bias and precision 
Bias was analyzed to determine accurate quantitation.  Bias was calculated for each 
analyte at 200%, 600%, and 1200% the minimum required sensitivities.  Each 
concentration was assessed for acceptability and the samples were averaged.  Most analytes 
displayed acceptable bias of ±20% (Table 8).  Brompheniramine, butalbital, and 
doxylamine were calculated to have bias values greater than 20%.  Zolpidem COOH and 
zopiclone could not be analyzed for bias because they were not detected.   
Precision was concurrently analyzed to determine the repeatability of results within 
run and between runs.  Precision was determined for each analyte with triplicate samples 
on five independent runs at 200%, 600%, and 1200% the minimum required sensitivities. 
Intra-precision results for each of the five runs were averages and evaluated at the low, 
medium, and high concentration for acceptability.  All the runs displayed intra-run 
precision within ±20%.  Inter-run precision was within ±20% for all analytes at all 
concentrations.  Zolpidem COOH and zopiclone could not be analyzed for precision 
because they were not detected.   
Table 8.  Bias and Precision Calculations 
Analyte Average Bias  
Average Precision %CV 
Intra-run Inter-run Grand Mean 
α-hydroxyalprazolam 4.46 
 






Amitriptyline 0.14 9.16 9.99 9.57
Amphetamine 7.47 6.06 6.46 6.26 
Benzoylecgonine -2.50 8.78 9.47 9.12 
Brompheniramine 20.55 11.94 15.42 13.68 
Butalbital 46.34 11.52 12.93 12.23 





Analyte Average Bias  
Average Precision %CV 
Intra-run Inter-run Grand Mean 
Chlorpheniramine 7.62 5.23 5.83 5.53 
Codeine 12.77 6.17 6.60 6.39 
Cyclobenzaprine 8.19 6.78 7.21 7.00 
Desipramine 4.57 5.87 6.43 6.15 
Dextromethorphan 10.69 13.56 15.64 14.60 
Diphenhydramine 10.96 4.95 5.45 5.20 
Doxylamine 28.96 11.10 12.21 11.66 
Fentanyl 6.730 4.63 5.12 4.87 
Hydrocodone 3.02 7.58 9.49 8.54 
Hydromorphone 4.07 5.25 5.76 5.51 
Imipramine 6.13 5.25 5.56 5.41 
Lorazepam 5.89 5.74 6.02 5.88 
mCPP 7.68 7.43 7.36 7.40 
MDA 9.49 5.02 5.61 5.32 
MDMA 11.21 4.90 5.68 5.29 
Meprobamate 3.73 5.41 6.42 5.92 
Methamphetamine 10.97 6.14 6.38 6.26 
Morphine 1.78 7.94 8.37 8.16 
Norchlorcyclizine 4.67 13.18 15.20 14.19 
Nordiazepam 9.76 5.02 5.41 5.22 
Norfentanyl 4.89 4.92 5.50 5.21 
Norketamine 8.94 5.11 5.48 5.30 
Nortriptyline 6.27 5.24 5.746 5.50 
Oxazepam 9.97 8.81 10.39 9.60 
Oxycodone 19.76 8.68 11.57 10.12 
Oxymorphone 4.28 6.43 6.82 6.63 
Phenobarbital 4.93 14.78 15.65 15.22 
Temazepam 6.61 5.19 5.47 5.33 
THCCOOH 18.77 9.48 9.52 9.50 
Tramadol 5.69 5.95 6.29 6.12 
 
3.2.3 Carryover 
Carryover was observed with signal intensity of 25% of the lowest calibrator for 
benzoylecgonine.  All other analytes were determined to be free from significant 






No matrix interference peaks were observed in blank urine samples which fell 
within 2% of a known analyte retention time and had a signal intensity greater than the 
calculated LOD.  Low levels of internal standard appeared for meprobamate, 
cyclobenzaprine, lorazepam, and desipramine in a sample with all analytes at 2000% 
their minimum required sensitivity but no spiked internal standard.  No interference 
peaks were observed in samples spiked with only internal standard and no analyte.   
3.2.5 Ion suppression or enhancement 
 The method displayed significant ion suppression/enhancement among several 
analytes.  Carisoprodol, desipramine, hydromorphone, imipramine, lorazepam, morphine, 
oxazepam, and oxymorphone were the only compounds to exhibit ionization suppression 
or enhancement effects in the acceptable range of 25% or less.   
Table 9. Ion Suppression/Enhancement Values 
Analyte Low Concentration (%) High concentration (%) 
α-hydroxyalprazolam 24.83 40.96155  
7-aminoclonazepam 19.96 36.18 
Amitriptyline -25.92 -5.32 
Amphetamine 16.84 -32.27 
Benzoylecgonine 105.29 3.11 
Brompheniramine -77.07 27.81 
Butalbital -19.49 -36.60 
Carisoprodol 16.16 0.06 
Chlorpheniramine -57.11 16.64 
Codeine 87.35 -9.17 
Cyclobenzaprine -22.41 15.85 
Desipramine -14.74 6.75 
Dextromethorphan -70.21 1.47 
Diphenhydramine -74.07 -20.71 
Doxylamine -73.97 -48.63 





Analyte Low Concentration (%) High concentration (%) 
Hydrocodone 90.50 -0.14 
Hydromorphone 9.83 1.46 
Imipramine -23.67 15.11 
Lorazepam -14.28 16.95 
mCPP 86.76 1.46 
MDA 58.73 -37.01 
MDMA 55.82 -11.33 
Meprobamate -41.11 -15.97 
Methamphetamine 32.83 -18.99 
Morphine 5.79 10.02 
Norchlorcyclizine -16.53 32.75 
Nordiazepam 24.34 37.44 
Norfentanyl 70.80 45.48 
Norketamine 57.53 -7.07 
Nortriptyline -65.01 0.56 
Oxazepam -7.08 12.52 
Oxycodone 129.16 8.68 
Oxymorphone 10.72 10.15 
Phenobarbital -69.59 -44.41 
Temazepam 16.17 25.72 
THCCOOH -67.11 50.49 
Tramadol 22.81 44.98 
Zolpidem COOH 112.35 54.77 
Zopiclone 135.67 9.29 
 
3.2.6 Recovery 
Recovery percentages using the SLE sample preparation are shown in Table 10.  
Recovery was moderate for amitriptyline, cyclobenzaprine, desipramine, imipramine, 
dextromethorphan, and diphenhydramine.  Recovery was poor for benzoylecgonine and 
THCCOOH.  Zolpidem COOH and zopiclone were not recovered after sample 
preparation.   
Table 10. Recovery Values 
Analyte Low Concentration Recovery (%) 










Analyte Low Concentration Recovery (%) 





 Amitriptyline 54.52 32.64 
Amphetamine 83.16 62.67 
Benzoylecgonine 6.31 6.08 
Brompheniramine 88.48 74.94 
Butalbital 79.77 71.09 
Carisoprodol 127.43 118.11 
Chlorpheniramine 82.41 71.39 
Codeine 103.98 68.95 
Cyclobenzaprine 55.98 44.20 
Desipramine 58.01 47.09 
Dextromethorphan 22.96 41.00 
Diphenhydramine 39.33 48.97 
Doxylamine 127.36 101.52 
Fentanyl 74.95 62.17 
Hydrocodone 103.77 87.61 
Hydromorphone 109.90 76.34 
Imipramine 57.23 44.81 
Lorazepam 66.35 69.95 
mCPP 84.94 73.22 
MDA 94.33 66.08 
MDMA 101.21 79.75 
Meprobamate 126.34 102.95 
Methamphetamine 82.29 56.04 
Morphine 99.70 72.19 
Norchlorcyclizine 67.67 52.25 
Nordiazepam 59.50 60.13 
Norfentanyl 98.49 95.24 
Norketamine 94.25 83.94 
Nortriptyline 24.29 41.89 
Oxazepam 64.28 66.83 
Oxycodone 118.58 89.37 
Oxymorphone 118.03 92.86 
Phenobarbital 84.18 70.82 
Temazepam 71.17 70.73 
THCCOOH 5.84 5.37 
Tramadol 101.26 90.98 
Zolpidem COOH 0 0 







4.1 Method Development 
4.1.1 Column 
Initial attempts at chromatography utilized a C18 column resulting in several 
analytes co-eluting such that a decrease in sensitivity because of competition for ionization 
was seen.  By implementing the phenyl hexyl column, more selective separation was 
observed allowing for greater signal intensity. Compounds such as doxylamine, 
chlorpheniramine, brompheniramine and dextromethorphan can overload residual silanol 
groups on a typical C18 column leading to poor peak shape (51).  Interactions with the 
hexyl linkers in the phenyl-hexyl column allow for better separation and more defined 
chromatography (51).   
 
4.1.2 Mobile phase  
Methanol was chosen as the organic solvent because of its weaker elution strength 
as compared with acetonitrile (11).  Analytes were retained in the column longer, allowing 
for matrix components to elute off in waste in the beginning of the run.  The weaker elution 
strength of methanol ensured analytes were eluted in a mobile phase with a higher organic 
content resulting in more effective de-solvation and enhanced electrospray response (11).   
Original analysis utilized 10mM ammonium formate in ultrapure water as the 
aqueous mobile phase resulting in low signal intensity when operating in negative mode.  





water.  Theoretically, a weak acid could provide additional protons at the ESI capillary tip, 
facilitating the creation of excess negative charge, and ultimately promoting analyte 
deprotonation (52).  Additional improvements in negative mode signal intensity could be 
made using acetic acid, which has a higher gas phase proton affinity (52).   
 
4.1.3 Separation of isobaric compounds 
Two analytes shared a precursor mass with one of their metabolites: morphine 
with hydromorphone, and codeine with hydrocodone.  Because the analyte-metabolite 
pairs have similar structures, they also exhibited similar fragmentation chemistry.  To 
ensure clear identification, different product ions were monitored, and the LC method 
was adjusted to ensure the pairs did not co-elute.  Using the LC method outlined by 
Zheng et al did not initially resolve morphine and hydromorphone fully and the LC 
method was adjusted to allow for further separation between the peaks (46).   
4.1.4 Optimizing for positive and negative ESI 
The fast polarity switching capabilities of the UniField Detector™ facilitated the 
acquisition of data for positive and negative ESI within one method (53).  The detector’s 
design allows for the near-simultaneous detection of both negative and positive ions 
without the use of high-voltage switching.  Negative ions are attracted to a fixed +6kV 
dynode.  An electron is released when the negative ion strikes the dynode, and the electron 
cascades down the series of increasingly positive dynodes to produce a signal (Figure 10). 
Positive ions are attracted to a high-energy dynode (HED) fixed at -6kV.  The positive ion 





electron then produces a signal in a similar manner as the negative ion: by cascading down 
the series of increasingly positive dynodes to the detector.  Polarity switching occurs in 
microseconds allowing for the detection of positive and negative ions regardless of elution 
time within one analytical method (53). 
 
Figure 10.  Schematic of the Unifield Detector.    
(A) The negative ion path through the detector; and (B) the positive ion path through the detector. 
Historically, barbiturates and THCCOOH exhibit a greater ionization efficiency in 
ESI negative mode and do not generate a significant response in ESI positive mode (24). 
Some analytes, such as THCCOOH, can be ionized in both positive and negative mode.  
Consideration must be given that an analyte measured in negative mode can still ionize and 
create interfering species for analysis in positive mode.  While the QSight was able to 
detect drugs in both positive and negative ionization mode, creating conditions for optimal 
ionization in a singular method proved challenging.  Butalbital displayed unacceptable bias 





show an acceptable linear response.  Inconsistent sample recovery could be contributing to 
THCCOOH’s low calibration coefficient.  Signal intensity for butalbital, phenobarbital, 
and THCCOOH was low considering their concentrations relative to other analytes.  Even 
if signal intensity remains low for analytes in negative mode the method still could be 
suitable for DFSA sample analysis because the minimum required sensitivities for the 
barbiturates is especially high.  
4.1.5 Scan time/duty-cycle optimization 
Given the number of analytes in this method, optimization of dwell times was 
exceedingly important.  MRM transitions require the MS to continuously scan the 
designated mass range for each transition.  Creating windows of scan time based on each 
analyte’s retention time can help maximize the dwell time for each analyte.  Utilizing a 
time-managed MRM allows for more data points at the critical time an analyte is expected 
to elute, thus improving peak shape.  The Simplicity software can calculate the optimal 
dwell time to provide sufficient points across a peak for acceptable bias and precision.  At 
least twelve points were observed on acceptable analyte peaks for this analytical method.   
Analytes that elute within thirty seconds of each other necessarily decrease the 
dwell time available for the machine to scan for each analyte’s m/z transitions.  Thus, as 
the number of closely eluting analytes increase, the dwell time for each transition 
decreases, and ultimately the sensitivity decreases.  One way to address unacceptable bias 
or precision would be to create a longer method, allowing larger differences between 





4.1.6 Sample Preparation 
The dilute-and-shoot sample preparation failed to give acceptable 
chromatography at dilution levels of 1:100 and 1:50. Several drugs exhibited poor peak 
shape, including split peaks and peak broadening.  For example, morphine exhibited peak 
splitting and low signal intensity with dilute-and-shoot preparation but gave a clean 
Gaussian shape at the same concentration with SLE sample preparation (Figure 11).  
 
Figure 11. Morphine peak comparison.  Morphine at 10 ng/mL concentration prepared via a 1:50 dilute 
and shoot (A) and SLE method (B) 
   Drugs that had low required minimum sensitivities suffered especially.  The peak 
for norfentanyl was not found in Calibrator 1, Calibrator 2, and the LQC sample for both 
dilutions.  This is not surprising, given Calibrator 1 contained norfentanyl at a 
concentration of 0.5 ng/mL, and would have been diluted to as little as 5 
picograms/mL.  The 1:3 sample preparation showed significant ion suppression or 
enhancement effects.  However, the SLE sample preparation samples also suffered from 







4.2 Method Validation 
4.2.1 Bias 
While most of the analytes displayed acceptable bias, calculated bias values for 
brompheniramine, butalbital, and doxylamine were greater than 20%.  The peak 
representing doxylamine was broad and consistently lacking in Gaussian shape.  The 
hydrophobic properties of doxylamine can lead to overloading of the residual silanol 
groups on the column leading to poor peak shape, but interactions with the hexyl linker in 
the column should enhance.  Similar interactions could impact chlorpheniramine, 
brompheniramine, and dextromethorphan.  Separation of chlorpheniramine, 
diphenhydramine, and dextromethorphan has been achieved on a phenyl-hexyl column 
while employing a basic strong mobile phase (pH 9.0).  Adjusting the pH of the organic 
mobile phase could help decrease the peak width and improve the precision results.   
4.2.2 Ion suppression or enhancement effects 
  Analysis of urine samples via ESI is susceptible to ion suppression effects.  Ion 
suppression occurs when more than one component in the ion source results in 
competition for ionization.  This leads to a decrease in signal intensity which can 
negatively impact the method’s limit of detection.  Ion suppression can be difficult to 
predict, with physiological changes and other variable matrix components causing 
variation in suppression between samples (8).  Salts and other urine components can 
increase ion suppression effects and were prominently seen in the 1:3 dilution.  The SLE 





binding them to the diatomaceous earth packed cartridge in the body of the SLE cartridge 
while the analytes are eluted, thus decreasing ion suppression and enhancement.  Given 
the number of closely eluting analytes, competition for ionization could be significantly 
impacting the number of analytes effectively ionized and detected.  By creating a method 
with a longer run time, the analytes would elute less closely, and ionization suppression 
or enhancement effects could be decreased.  The pH also can have significant impact on 
ionization and should be modified in future work to optimize ionization.   
4.2.3 Recovery 
While recovery was evaluated for this method, ASB 036 does not require it for 
method validation (48).  Namely, a method may have low or moderate recovery but still 
capable of meeting the cutoffs indicated in ASB 121.  A generic SLE procedure was 
selected for this method because of the mixture of acidic, basic, and neutral analytes in 
the assay.  The initial addition of ammonium hydroxide was intended to increase the 
affinity of acidic analytes, such as opiates, for the SLE column.  Zopiclone and zolpidem 
carboxylic acid displayed appropriate signal intensity and chromatographic separation in 
all post extraction samples and samples that underwent dilute and shoot preparation.  
However, both Z-drugs and their stable isotope internal standards were not detected in 
any sample that underwent the enzymatic hydrolysis and SLE preparation.  Zolpidem 
carboxylic acid has been detected via LC-MS after enzymatic hydrolysis with 
IMCSzymeTM utilizing the same MRM transitions monitored in this work (54).  Previous 





Isolute® Supported Liquid Extraction SLE+ cartridges (55).  Successful elution of 
zolpidem carboxylic acid has been achieved using 2% formic acid preconditioning and 
methanol as the eluent (54).    Zolpidem carboxylic acid and zopiclone most likely were 
not eluted by the ethyl acetate and remained bound in the diatomaceous earth matrix of 
the SLE cartridge.  Changes to the SLE eluent to replicate the protocol of Feng, 
Cummings, and McIntire would likely allow recovery of zolpidem COOH and zopiclone 
but may also impact recovery of other analytes.  
Recovery of volatile compounds like methamphetamine and amphetamine could 
be further optimized by adding a mixture of 0.01% nitric acid in methanol to the eluent 
samples before evaporating them to dryness (56).  THCCOOH sample loss during the 
extraction process could lead to variability in calibrators and quality control samples, 
which could explain the poor linearity, bias, and precision results.  However, THCCOOH 
has shown similarly poor bias and precision results in previous multi-drug LC-MS-MS 
methods (45).  A challenging aspect of measuring urinary cannabinoids is their common 
adsorption to sample preparation materials, which could explain the poor recovery observed 
for this analytical method. (57).  A comparison of sample extraction for THCCOOH and 
other cannabinoids found that C18 SPE provided higher sample recoveries than 
diatomaceous earth (57).  Additionally, they utilized a 96-well plate sample preparation 
which limited the number of transfers required for sample preparation.  Wei, Wang, and 





However, their analysis only examined cannabinoids, and their preparation would need to be 
tested for suitability with the other analytes in ASB 121.  
4.2.2 Limit of Detection 
Because the collection of DFSA samples is frequently delayed and many common 
DFSA drugs require low doses to induce the desired effects, an analytical method 
developed for DFSA samples must be highly sensitive.  ASB 121 defines the limit of 
detection as an estimate of the lowest analyte concentration that can be reliably identified 
and differentiated from blank matrix (14). Each analyte’s required minimum sensitivity 
was derived from the literature or an estimated concentration of single dose usage (14).  
For the developed analytical method, the theoretical limit of detection was below the 
required minimum sensitivity dictated by ASB 121 for all analytes except THCCOOH, 
zopiclone, and zolpidem COOH.  The LC-MS method could detect all analytes below the 
required minimum sensitivity when added post extraction.  Based on these results, poor 
sample recovery during the SLE protocol likely accounts for the high LOD values for 
THCCOOH.  The previously discussed changes to sample preparation could improve 
recovery and allow the method to meet the ASB 121 required sensitivities.   
4.2.2 Quantitative or Qualitative Application 
 While this method was validated for quantitative application, consideration 
should be given to whether a quantitative result is necessary.  Quantification would be 
necessary to estimate the magnitude of the dose and infer the potential incapacitating 





with caution.  Many unique variables impact the amount of a drug detected in urine, and 
metabolites of previously ingested substances can be detected while not contributing to 
intoxication (41).  As such, quantitation in urine samples is not always recommended 
(58).  Drug identification above the minimum required threshold may be sufficient for 
many applications.   







A quantitative assay was developed to attempt to meet the minimum scope and 
sensitivity requirements laid out in ASB 121.  The developed method included the 
detection of 37 analytes in positive mode, and 3 in negative mode.  The LC-MS method 
was able to detect all analytes, with retention times between 2 and 9 minutes.  Two 
analytes, zolpidem COOH and zopiclone, were lost during sample preparation, likely 
because they did not elute off the SLE cartridge.  All analytes displayed linearity with 
correlation coefficients greater than 0.98 apart from THCCOOH and the two undetected 
Z-drugs.  For the analytes displaying acceptable linearity, the method was able to meet 
the minimum sensitivity requirements.  Significant ionization suppression and 
enhancement effects were observed for several analytes.  Doxylamine and butalbital 
displayed unacceptable bias.   
There is potential in the developed method for an effective quantitative assay for 
DFSA urine samples.  For many analytes, the method is already effective and could be 
utilized in its current state.  Further optimization of sample preparation could produce a 






6. FUTURE DIRECTIONS 
 Several improvements can move this method toward a valid quantitative assay for 
DFSA urine samples.  Changes to sample preparation to allow better recovery of 
zopiclone, zolpidem COOH, benzoylecgonine, and THCCOOH are necessary.  
Specifically, ethyl acetate is likely a poor eluent for zopiclone and zolpidem COOH.  
Methanol elution after a 2% formic acid preconditioning should be attempted based on 
the success of previous studies (54).  Different mobile phase pH should be explored to 
narrow doxylamine’s peak therefore improving bias and precision results for the analyte.  
Ion suppression or enhancement effects may be improved with a longer run time to 
decrease coelution and competition of ionization.  Additional blank samples should be 
tested to determine the impact of the heightened ionization suppression/enhancement 
observed on each analyte’s LOD.   
 
Upon improvement, patient urine samples should be tested to validate the efficacy 
and recovery after enzymatic hydrolysis.  Additional interference testing with commonly 







Table A 11. Certified reference standard information. 
Analyte Provider Lot Number 
(-)-11-nor-9-carboxy- Δ9-THC-D3 Cayman 0571148-3 
(-)-11-nor-9-carboxy-Δ9-THC Cayman 0571148-3 
(±)-Amphetamine Cerilliant FE04061701 
(±)-Amphetamine-D6 Cerilliant FE08301801 
(±)-MDA Cerilliant FE05061901 
(±)-MDA-D5 Cerilliant FE01131506 
(±)-MDMA Cerilliant FE06141804 
(±)-MDMA-D5 Cerilliant FE02211702 
(±)-Methamphetamine Cerilliant FE12141602 
(±)-Methamphetamine-D5 Cerilliant FE03211801 
(±)-Norketamine HCl Cerilliant FN10231801 
(±)-Norketamine-D4 HCl Cerilliant FN10231801 
1-(3-Chlorophenyl)piperazine (mCPP) HCl Cerilliant FN03212001  
1-(3-Chlorophenyl)piperazine-D8 HCl Cerilliant FN03232014 
7-Aminoclonazepam Cerilliant FN11171503 
7-Aminoclonazepam-D4 Cerilliant FN12081502  
alpha-Hydroxyalprazolam Cerilliant FN07051601 
alpha-Hydroxyalprazolam-D5 Cerilliant FN01261703 
Amitriptyline HCl Cerilliant FN06131706 
Amitriptyline-D3 HCl Cerilliant FN04151601 
Benzoylecgonine Cerilliant FE01061604 
Benzoylecgonine-D8 Cerilliant FE06071702 
Brompheniramine maleate Cerilliant FN06301701 
Butalbital Cerilliant FE08101701 
Butalbital-D5 Cerilliant FE02281072 
Carisoprodol Cerilliant FE03032012 
Carisprodol-D7 Cerilliant FE08111701 
Chlorpheniramine maleate Cerilliant FN02061903 
Chlorpheniramine-D6 maleate Cerilliant FN07071604 
Cis-Tramadol HCl Cayman 0572837 
Codeine Cerilliant FE11021502 
Codeine-D6 Cerilliant FE06221701 
Cyclobenzaprine HCl Cayman 522139 
Cyclobenzaprine-d3 HCl Cayman 529241 
Desipramine HCl Cerilliant FN06301705 
Desipramine-D3 HCl Cerilliant FN03281701 
Dextromethorphan Cayman 0581522 
Dextromethorphan-D3 Cerilliant FN02031706 
Diphenhydramine HCl Cerilliant FN02212011 
Diphenydramine-D3 Cerilliant FN03152001 
Doxylamine succinate Cerilliant FN11131904 
Doxylamine-D5 Cerilliant FN05132001 
Fentanyl Cerilliant FE06151802 
Fentanyl-D5 Cerilliant FE07281604 





Analyte Provider Lot Number 
Hydrocodone-D3 Cerilliant FE07311801 
Hydromorphone Cerilliant FE08011802 
Hydromorphone-D6 Cerilliant FE08271801 
Imipramine HCl Cerilliant FN07021901 
Imipramine-D3  Cerilliant FN05311901 
Lorazepam Cerilliant FE10151502  
Lorazepam-D4 Cerilliant FE10021702 
Meprobamate Cerilliant FE03252001 
Meprobamate-D3 Cerilliant FE06301704 
Morphine Cerilliant FE06231704 
Morphine-D6 Cerilliant FE10241701 
Nordiazepam Cerilliant FE11181503 
Nordiazepam-D5 Cerilliant FE11201801 
Norfentanyl oxalate Cerilliant FN10051802 
Norfentanyl-D5 oxalate Cerilliant FN05131603 
Norketamine HCl Cayman 0572743 
Nortriptyline- D3 HCl Cerilliant FN09161904 
Nortriptyline HCl Cerilliant FN11021803 
Oxazepam Cerilliant FE05261603 
Oxazepam-D5 Cerilliant FE02051602 
Oxycodone Cerilliant FE08241701 
Oxycodone-D6 Cerilliant FE09201701 
Oxymorphone Lipomed 2406.1B6.1L1 
Oxymorphone-D3 Lipomed 1229.1B3.1L2 
Phenobarbital Cerilliant FE08021601 
Phenobarbital-D5 Cerilliant FE08091702 
Temazepam Cerilliant FE04231903 
Temazepam-D5 Cerilliant FE09271701 
Zolpidem Phenyl-4-carboxylic acid Cerilliant FN10031902 
Zolpidem Phenyl-4-carboxylic acid-D4 Cerilliant FN07251708 
Zopiclone Cayman 0582124 







Table A 12.  R squared Values for Calibration Model Runs. 
Analyte Run 1 R2 Run 2 R2 Run 3 R2 Run 4 R2 Run 5 R2 
α-hydroxyalprazolam 0.9915 0.991 0.983 0.9945 0.987 
7-aminoclonazepam 0.989 0.9918 0.9924 0.9941 0.9985 
Amitriptyline 0.989 0.987 0.985 0.991 0.9918 
Amphetamine 0.9941 0.9941 0.995 0.9975 0.9966 
Benzoylecgonine 0.9935 0.9902 0.9935 0.981 0.9935 
Brompheniramine 0.989 0.9945 0.9924 0.9979 0.99 
Butalbital 0.9959 0.9906 0.9902 0.982 0.9934 
Carisoprodol 0.9926 0.9901 0.992 0.999 0.9975 
Chlorpheniramine 0.993 0.987 0.9907 0.9985 0.998 
Codeine 0.9926 0.9938 0.994 0.9974 0.9975 
Cyclobenzaprine 0.9907 0.989 0.989 0.9969 0.9963 
Desipramine 0.9948 0.989 0.9916 0.9977 0.9978 
Dextromethorphan 0.993 0.9956 0.9981 0.9987 0.9965 
Diphenhydramine 0.987 0.985 0.9918 0.9972 0.9987 
Doxylamine 0.985 0.9919 0.9958 0.9966 0.9945 
Fentanyl 0.9922 0.9921 0.9971 0.9973 0.9982 
Hydrocodone 0.9909 0.984 0.9915 0.9971 0.9974 
Hydromorphone 0.993 0.981 0.9943 0.9989 0.9977 
Imipramine 0.99 0.987 0.9926 0.9964 0.9969 
Lorazepam 0.9905 0.9912 0.9916 0.9955 0.9973 
mCPP 0.9904 0.9907 0.9967 0.9969 0.9971 
MDA 0.9924 0.9907 0.9944 0.9983 0.997 
MDMA 0.9917 0.993 0.9918 0.9969 0.997 
Meprobamate 0.9943 0.9926 0.9922 0.99932 0.9969 
Methamphetamine 0.9948 0.9903 0.9923 0.9972 0.9976 
Morphine 0.9937 0.99 0.9952 0.9983 0.9969 
Norchlorcylizine 0.981 0.982 0.9978 0.99 0.983 
Nordiazepam 0.9909 0.9924 0.9921 0.9975 0.997 
Norfentanyl 0.9932 0.9938 0.9938 0.9973 0.9967 
Norketamine 0.9907 0.989 0.9945 0.9968 0.9951 
Nortriptyline 0.9903 0.9904 0.9937 0.9949 0.9974 
Oxazepam 0.9913 0.9959 0.992 0.9945 0.9934 
Oxycodone 0.9946 0.9945 0.9961 0.9967 0.9968 
Oxymorphone 0.9921 0.9923 0.998 0.9949 0.997 
Phenobarbital 0.994 0.994 0.985 0.9939 0.982 
Temazepam 0.9905 0.9929 0.9918 0.9975 0.9957 
THCCOOH 0.959 0.906 0.944 0.947 0.991 
Tramadol 0.9923 0.9914 0.988 0.9986 0.9973 
Zolpidem COOH N/A N/A N/A N/A N/A 
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